PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES. (23rd June 2022) - Shadman, M.; Flinn, I. W.; Kingsley, E. C.; Freeman, B.; Levy, M. Y.; Cultrera, J.; Farber, C. M.; Chaudhry, A.; Porter, R.; Crescenzo, R.; Idoine, A.; Zhang, X.; et al.